All In Biotech

NDA 021948 · Pfizer

Eraxis

Anidulafungin · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 17, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 17, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

15 Phase 3, 0 recruiting

FAERS reports

1,627

1,582 serious, 692 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 17, 2006 Original approval · Type 6 - New Indication (no longer used) · priority review LabelReviewLetter
1 products under this application
  • ERAXIS · ANIDULAFUNGIN 50MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Anidulafungin" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective393
  • off label use187
  • multiple organ dysfunction syndrome174
  • septic shock128
  • sepsis118
  • pneumonia94
  • candida infection92
  • pyrexia92
  • neutropenia85
  • death80
  • drug resistance72
  • condition aggravated70

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20068
200718
200812
200924
201036
201147
201228
201324
201422
201521
201652
201770
2018118
2019122
2020123
2021138
2022189
2023174
2024157
2025145
202699

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eraxis (Anidulafungin)

2024 spending

$483K

Beneficiaries

134

529 claims

Per beneficiary

$3,602

$92.83 per unit

View as table
YearSpending
2020$590,076
2021$759,886
2022$475,972
2023$593,317
2024$482,685

Part B: Eraxis* (Anidulafungin*) · HCPCS J0348

2024 spending

$7K

Beneficiaries

11

128 claims

Per beneficiary

$599

2024 ASP limit $0.48 per unit

View as table
YearSpending
2020$6,231
2021$9,647
2022$17,869
2023$7,547
2024$6,594

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.